Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 152Fluorouracil 137Gemcitabine 118Bevacizumab 116Leucovorin 106Specimen Handling 105Capecitabine 96pembrolizumab 90Magnetic Resonance Spectroscopy 83Nivolumab 79Cisplatin 79Irinotecan 71durvalumab 64Cetuximab 62Biopsy 61Paclitaxel 60130-nm albumin-bound paclitaxel 59Radiotherapy 46atezolizumab 45Albumin-Bound Paclitaxel 37Taxes 36Carboplatin 36Folfox protocol 35Drug Therapy 32Cyclophosphamide 30lenvatinib 29dehydroftorafur 29tislelizumab 27sintilimab 27Radiation 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
anetumab ravtansine × Gastrointestinal × 90 days × Clear all
NCT03816358 2026-05-13

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡